LGD-3303
Muscle & Strength · SARM
Tier D
Bottom line
Read Off Label grades LGD-3303 as D (3.3/10) based on very weak evidence, unclear benefit magnitude, and a unclear-risk safety profile.
Preclinical osteoporosis candidate from Ligand.
Typical use: No established human dosing — NOT FDA-approved; gray market; banned sport.
What this is
Preclinical osteoporosis candidate from Ligand. Never advanced to clinical development. Exists in the research-chemical market primarily as a novelty; essentially no safety or efficacy information in humans.
Mechanism
Strong non-steroidal SARM from Ligand Pharmaceuticals — more androgenic than LGD-4033; bone and muscle anabolic in preclinical; no meaningful human trial program
Dose & route
No established human dosing
Citations
- https://pubmed.ncbi.nlm.nih.gov/19864487/
- https://pubmed.ncbi.nlm.nih.gov/21782036/
- https://pubmed.ncbi.nlm.nih.gov/29378245/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does LGD-3303 work?
- Read Off Label rates the evidence for LGD-3303 as Very Weak and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Preclinical osteoporosis candidate from Ligand.
- Is LGD-3303 safe?
- LGD-3303 has a unclear risk profile in published human data. Legal status: NOT FDA-approved; gray market; banned sport. This is not medical advice — see the disclaimer.
- What is the typical dose for LGD-3303?
- No established human dosing
- How does LGD-3303 work?
- Strong non-steroidal SARM from Ligand Pharmaceuticals — more androgenic than LGD-4033; bone and muscle anabolic in preclinical; no meaningful human trial program
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.